Tools to measure and stimulate activity in brain tissue
The mission of this portfolio is to develop technologies offering novel therapy and diagnosis targeting the brain and the peripheral nervous system, increasing understanding of the electrical activity in the brain linked to brain-related diseases.
| Number of projects in portfolio | 9 |
| Projects | HYPERSTIM | MINIGRAPH | INTRECOM | NEMO BMI | CITRUS | MICROVASC | UPSIDE | CROSSBRAIN | HYPERPROBE |
| Portfolio run-time | starting October 2022 for up to 60 months |
| Total budget | €37 million |
| Responsible EIC Programme Manager | *From 2022 to 2024 Programme Manager Enric Claverol-Tinturé was leading this portfolio. |
| Portfolio output | Strategic plan Activity report for the 2nd year |
Emerging technologies in cell and gene therapy
This mission of this portfolio is the development of emerging technological solutions to advance cell therapy manufacturing and products to a clinical stage, improving adoptive cell therapies, identifying next generation cell therapies for cancer, personalising cell therapy to treat cancer patients, improving the effectiveness and lowering risks of gene delivery systems and improving gene therapy manufacturing processes and production.
| Number of projects in portfolio | 9 |
| Projects | AIPSC | SMARTER | MUTAVAC | T-FITNESS | PAT4CGT | X-PAND | EdiGenT | AAVolution | NOVISTEM |
| Portfolio run-time | starting October 2022 for up to 60 months |
| Total budget | €24 million |
| Responsible EIC Programme Manager | *From 2022 to 2024 Programme Manager Iordanis Arzimanoglou was leading this portfolio. |
| Portfolio output | Strategic plan Activity report for the 2nd year |
Engineered living materials (ELMs)
The mission of the portfolio is to support the development of new technologies and platforms that enable the controlled production of made-on-demand living materials with multiple predictable dynamic functionalities, shapes and scales, and to build a community of researchers and innovators in ELMs through portfolio’s activities.
| Number of projects in portfolio | 10 |
| Projects | BIOACTION | Bio-hHOST | BioRobotMiniHeart | Fungateria | ISOS | LoopOfFun | NextSkins | Prism-LT | REMEDY | SUMO |
| Portfolio run-time | starting November 2022 for up to 60 months |
| Total budget | €30 million |
| Responsible EIC Programme Manager | *From 2022 to 2024 Programme Manager Iordanis Arzimanoglou was leading this portfolio. |
| Portfolio outputs | Strategy plan Activity report for the 2nd year Website Portfolio brochure |
Cardiogenomics
The mission of the portfolio is to pave the way for novel therapies for major cardiovascular diseases conditions including haemorrhagic and ischemic stroke, aneurysm, cardiomyopathy and certain types of arrhythmias and other conditions, for which no effective treatments are currently available.
| Number of projects in portfolio | 7 |
| Projects | TargetMI | B-specific | NaV1.5-CARED | MIRACLE | DCM-NEXT | IMPACT | CARDIOREPAIR |
| Portfolio run-time | starting October 2023 for up to 60 months |
| Total budget | €29 million |
| Responsible EIC Programme Manager | *From 2022 to 2024 Programme Manager Iordanis Arzimanoglou was leading this portfolio. |
| Portfolio output | Strategy plan |
Towards the Healthcare Continuum
The mission is to develop non-invasive personal imaging and sensing modality technologies and monitoring systems - starting at very low technology readiness levels - to identify early signs of disease.
| Number of projects in portfolio | 9 |
| Projects | BREATH-SENSE | MuSiC4Diabetes | WOUNDSENS | VOCORDER | MiWear | STIMULUS | KERMIT | Blood2Power | IV-Lab |
| Portfolio run-time | starting October 2023 for up to 60 months |
| Total budget | €32 million |
| Responsible EIC Programme Manager | *From 2022 to 2024 Programme Manager Enric Claverol-Tinturé was leading this portfolio. |
| Portfolio output | Strategy plan |